50 Northern Avenue
About Ikena Oncology
Ikena, headquartered in the biotech hub of Boston, Massachusetts, is dedicated to bringing next generation oncology therapies to patients suffering from cancer. We are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.
Our name, Ikena, is derived from the combination of “I” which refers to the individual or the patient and “ken” which means understanding or knowledge, thereby illustrating our commitment to using our insights to identify which patients are most likely to benefit from our therapies. Ikena is also a Hawaiian word which means seeing, knowing, and having insight into the future. Our symbol further embodies our focus on pinpointing biomarkers that illuminate our knowledge into which patients may benefit from our therapies.
Today, our company is comprised of dedicated talented professionals who are striving to see, know and understand what drives every patient’s cancer, with the ultimate goal of making a difference in patients’ lives.
17 articles with Ikena Oncology
11/20/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Prominent Scientists and Clinical Investigators Bring Extensive Strategic Expertise in Targeted Oncology Across the Spectrum from Discovery and Translation to Development
Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting
Ikena Oncology, Inc. (“Ikena”), a clinical-stage, biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced that a poster presentation will take place at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting, taking place virtually November 9-14, 2020
8/21/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Industry Veteran in Targeted Oncology Joins as Ikena Advances Multiple Clinical and Preclinical Programs
Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade
Ikena Oncology, a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced the publication in Nature Communications of a preclinical collaboration with the Jedd Wolchok and Taha Merghoub team at Memorial Sloan Kettering Cancer Center (MSK)
Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway
Novel TEAD Inhibitor Candidates Demonstrate Anti-Proliferative and Anti-Tumor Effects in Preclinical Models Poster Released Online at the 2020 American Association for Cancer Research Virtual Annual Meeting II BOSTON--( BUSINESS WIRE )-- Ikena Oncology, a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced the presentation of new preclinical research highlighting th
Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors
Ikena Oncology, a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced dosing of the first patient in the first Phase 1 clinical trial evaluating IK-175 (formerly KYN-175), an internally-developed, orally administered, selective aryl hydrocarbon receptor (AHR) antagonist, in patients with advanced solid tumors.
Kyn Therapeutics, a clinical-stage biotechnology company, today announced it is rebranding to Ikena Oncology.
5/10/2019Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
Kyn Therapeutics, a clinical-stage biotechnology company developing highly differentiated cancer immunotherapies, today announced the appointment of Jeffrey Ecsedy, Ph.D., as its chief scientific officer and Jason Sager, M.D., as its chief medical officer.
Kyn Therapeutics today announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer.
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
- Celgene gains exclusive options to two Kyn therapeutic programs
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck
Two studies to evaluate ARY-007 in combination with KEYTRUDA® (pembrolizumab) in checkpoint-resistant solid tumors
Ronald Renaud to serve as chairman of Kyn’s board of directors
Investors were Atlas Venture and OrbiMed.